Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 16/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923791 | 0.87 | KCNH3 (0.97) | KCNH3 | |
| SCHEMBL1391524 | 0.85 | KCNH3 (0.70) | KCNH3MEN1KMT2ALMNATDP1 | |
| SCHEMBL1391646 | 0.84 | IDH2 (0.56) | KCNH3LMNAMAPTMAPK1 | |
| SCHEMBL3427059 | 0.84 | KCNH3 (0.56) | KCNH3MEN1KMT2ALMNATDP1 | |
| SCHEMBL14447121 | 0.84 | POLB (0.66) | KCNH3MEN1KMT2ALMNATDP1 | |
| SCHEMBL1393055 | 0.83 | KCNH3 (0.56) | KCNH3MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL1391356 | 0.81 | KCNH3 (0.52) | KCNH3MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL1392273 | 0.79 | SLC2A1 (0.62) | KCNH3MEN1KMT2ALMNATDP1 | |
| SCHEMBL27344687 | 0.77 | KCNH3 (0.79) | KCNH3LMNATDP1MAPTNPSR1 | |
| SCHEMBL10243636 | 0.77 | MAPT (0.79) | KCNH3MEN1KMT2ALMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | HAVCR2, ZC3HAV1, MAVS | KCNH3 3535/4885MEN1 4840/4885KMT2A 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.